Journals / Marmara Pharmaceutical Journal / 2018 / Cilt: 22 - Sayı: 2

QSAR studies of novel iminochromene derivatives as carbonyl reductase 1 (CBR1) inhibitors

Pages
227–236
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The obtained results suggested that the PCA method could be more helpful to predict the biological activity of iminochromene derivatives.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:A quantitative Structure-Activity Relationship (QSAR) model was applied to the prediction of the activity of iminochromene derivatives.
📊
Key Findings & Data:The inhibition activity of 34 carbonyl reductase 1 (CBR1) inhibitors were modeled with the descriptors of quantum-chemical calculations with density functional theory (DFT) method at B3LYP/6‒31G level.
💡
Conclusion & Impact:The obtained results suggested that the PCA method could be more helpful to predict the biological activity of iminochromene derivatives.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

A quantitative Structure-Activity Relationship (QSAR) model was applied to the prediction of the activity of iminochromene derivatives. The inhibition activity of 34 carbonyl reductase 1 (CBR1) inhibitors were modeled with the descriptors of quantum-chemical calculations with density functional theory (DFT) method at B3LYP/6‒31G level. This study was conducted using the multiple linear regressions (MLR), the partial least square analysis (PLS) and the principal component analysis (PCA) method. Results displayed that the MLR method predicted of activity good enough. The best model, with seven descriptors was selected. Also it indicates very good consistency towards data variations for the validation methods. The predicted values of activities are in suitable agreement with the experimental results. The obtained results suggested that the PCA method could be more helpful to predict the biological activity of iminochromene derivatives. It is anticipated to be useful to predict the activity of other compounds in the same groups.

🔖

Cite This Article

MAHANİ, N. M., ZARANDİ, A. M., HORZADEH, A. (2018). QSAR studies of novel iminochromene derivatives as carbonyl reductase 1 (CBR1) inhibitors. Marmara Pharmaceutical Journal, Cilt: 22 - Sayı: 2, 227–236. https://ajindex.com/articles/283598

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Hoffmann F, Maser E. Carbonyl reductases and pluripotent hydroxysteroid dehydrogenases of the short-chain dehydrogenase/reductase superfamily. Drug Metab Rev. 2007; 39(1): 87-144
  2. Oppermann U. Carbonyl reductases: the complex relationships of mammalian carbonyl- and quinone-reducing enzymes and their role in physiology. Annu Rev Pharmacol Toxicol.2007; 47: 293-322
  3. Malatkova P, Maser E, Wsol V. Human carbonyl reductases. Curr Drug Metab. 2010; 11(8): 639-658
  4. Wermuth B. Purification and properties of an NADPH-dependent carbonyl reductase from human brain. Relationship to prostaglandin 9-ketoreductase and xenobiotic ketone reductase. J BiolChem. 1981; 256(3):1206-1213
  5. Tanaka M, Bateman R, Rauh D, Vaisberg E, Ramachandani S, Zhang C, Hansen KC,Burlingame AL, Trautman JK, Shokat KM, Adams CL. An unbiased cell morphology-based screen for new, biologically active small molecules. PLoS Biol.2005; 3(5):128-135
  6. Zimmermann TJ, Niesen FH, Pilka ES, Knapp S, Oppermann U, Maier ME. Discovery of a potent and selective inhibitor for human carbonyl reductase 1 from propionate scanning applied to the macrolide zearalenone. Bioorg Med Chem. 2009; 17(2):530-536
  7. Ito Y, Mitani T, Harada N, Isayama A, Tanimori S, Takenaka S, Nakano Y, Inui H, Yamaji R. Identification of carbonyl reductase 1 as a resveratrol-binding protein by affinity chromatography using 4'-amino-3,5-dihydroxy-trans-stilbene. J Nutr Sci Vitaminol. (Tokyo) 2013; 59(4): 358-364
  8. Huang W, Ding L, Huang Q, Hu H, Liu S, Yang X, Hu X, Dang Y, Shen S, Li J, Ji X, Jiang S, Liu JO, Yu L. Carbonyl reductase 1 as a novel target of (-)-epigallocatechin gallate against hepatocellular carcinoma. Hepatology2010; 52(2):703-714
  9. Gonzalez-Covarrubias V, Kalabus JL, Blanco JG. Inhibition of polymorphic human carbonyl reductase 1 (CBR1) by the cardioprotectant flavonoid 7-monohydroxyethyl rutoside (monoHER). Pharm Res. 2008; 25(7):1730-1734
  10. Carlquist M, Frejd T, Gorwa-Grauslund MF. Flavonoids as inhibitors of human carbonyl reductase 1. Chem Biol Interact. 2008; 174(2):98-108
  11. Hu D, Miyagi N, Arai Y, Oguri T, Miura T, Nishinaka T, Terada T, Gouda H, El-Kabbani O, Xia S, Toyooka N, Hara A, Matsunaga T, Ikari A, Endo S. Synthesis of 8-hydroxy-2-iminochromene derivatives as selective and potent inhibitors of human carbonyl reductase 1. Org Biomol Chem. 2015;13(27): 7487-7499
  12. Hadjipavlou-Litina D. Review: reevaluation and new results in quantitative structure-activity studies o